Risankizumab Intravenous Infusion for Adults

Who can administer

May be administered by registered competent doctor or nurse/midwife

Important information

  • Consider premedication (antihistamine and/or paracetamol) if infusion-related reactions are anticipated (ref 1)
  • In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded
  • Confirm patient does not have a history of current or recent infection, or recent exposure to chicken pox or TB
  • Immunisations
    • Prior to initiating therapy with risankizumab, completion of all appropriate immunisations should be considered according to current immunisation guidelines
    • If a patient has received live vaccination (viral or bacterial), it is recommended to wait at least 4 weeks prior to starting treatment with risankizumab
    • Patients treated with risankizumab should not receive live vaccines during treatment and for at least 21 weeks after treatment

Available preparations

Skyrizi 600 mg per 10mL vial

Reconstitution

Already in solution

Dilute further prior to administration

Infusion fluids

Sodium chloride 0.9% or Glucose 5%

Methods of intravenous administration

Intermittent intravenous infusion (using an electronically controlled infusion device)

  • This is a monoclonal antibody. Reduce direct handling to a minimum and wear appropriate personal protective equipment. (ref 1)
  • Prepare and administer according to the following table
Indication Intravenous induction dose Number of 600mg/10mL vials Volume of infusion fluid Infusion duration
Crohn's disease 600mg 1 100, 250 or 500mL at least 60 minutes
Ulcerative colitis 1200mg 2 250 or 500mL at least 120 minutes
Do not shake the solution in the vial or in the infusion bag  

Dose in adults

Crohn's disease

  • Give 600mg at week 0,4 and 8
  • Change to subcutaneous injection thereafter - see manufacturer's instructions for doses

 Ulcerative colitis

  • Give 1200mg at week 0,4 and 8
  • Change to subcutaneous injection thereafter - see manufacturer's instructions for doses

Renal or hepatic impairment

  • No dose adjustment required

Storage

Store between 2 and 80C

References

SPC July 2024

1: Injectable medicines guide, Medusa, Downloaded Oct 2024

Therapeutic classification

Immunosuppressant, interleukin inhibitor